{
    "nctId": "NCT01190566",
    "briefTitle": "PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer",
    "officialTitle": "PET-MR Fusion Imaging and Surrogate Marker for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 57,
    "primaryOutcomeMeasure": "Patholocial Response to Chemotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Pathologically confirmed breast cancer\n* Clinical stage IIb, IIIa, IIIb, IIIc\n* Must have measurable disease\n* Performance status of ECOG 0-2\n* Adequate, bone marrow, liver, heart, and renal function\n* Who did not receive chemotherapy for breast cancer\n* Must agree with and signed informed consent\n\nExclusion Criteria:\n\n* Prior history of cancer besides breast cancer\n* Active bacterial infection\n* Pregnant or lactating women\n* Psychological disease or seizure\n* History of arrhythmia, congestive heart failure, myocardial infarct, or unstable angina\n* Male breast cancer\n* Who had a pacemaker or history of open heart surgery",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}